Allstate Corp vs AstraZeneca plc — how do they compare? Allstate Corp trades at $262 (market cap $68.19B), while AstraZeneca plc trades at $158.56 (market cap $250.84B). The key difference: AstraZeneca plc is far larger — about 3.7× Allstate Corp's market cap, and AstraZeneca plc pays the higher dividend (1.97%). Which is the better fit depends on your goals.
| ALL | AZN | |
|---|---|---|
Market Cap | $68.19B | $250.84B |
Sector | Financials | Health |
52-Week High | $275.11 | $209.48 |
52-Week Low | $190.00 | $147.06 |
Enterprise Value | $76.84B | $278.12B |
Dividend Yield | 1.6% | 1.97% |
Signals from Pluang's Aura AI — not financial advice
Allstate (ALL) trades at $267.00, down 2.95% on the day, but maintains a bullish technical signal with strong fundamental momentum. The company reported robust Q2 2026 earnings of $8.99 per share, beating estimates, and has consistently exceeded expectations in recent quarters. Revenue growth is steady, with 2025 revenue at $67.07 billion and net income margin improving to 19.19%. The stock is attractively valued with a P/E of 5.35 and offers a dividend, with recent payouts of $1.08 per share.
The outlook for ALL is positive, driven by strong underwriting performance and earnings beats, though sustainability of peak profitability is a concern. Investment opportunity lies in its low valuation and dividend yield, but risks include potential normalization of underwriting results and competitive pressures. Analyst consensus is mixed with a $266.54 price target, indicating limited near-term upside from current levels.
No Aura AI signal available yet.
Trailing returns across standard periods
Latest headlines on both assets
On the basis of premium sales, Allstate is one of the largest U.S. property and casualty insurers. Personal auto represents the largest percentage of revenue, but the company offers homeowners insurance and other insurance products. Allstate products are sold in North America primarily by about 10,000 agencies.
Read more on ALL →A merger between Astra of Sweden and Zeneca Group of the United Kingdom formed AstraZeneca in 1999. The firm sells branded drugs across several major therapeutic classes, including gastrointestinal, diabetes, cardiovascular, respiratory, cancer, and immunology. The majority of sales come from international markets with the United States representing close to one third of its sales.
Read more on AZN →